Graham Doyle

Graham Doyle is an Executive Director and Head of European MedTech in the Equity Research department at UBS in London.13 He has over 10 years of experience as a healthcare equity research analyst covering European pharmaceutical, medical technology, and healthcare services companies.1

Professional Experience

• Executive Director, Equity Research at UBS (October 2021 - Present)1
• Healthcare Equity Research Analyst at Liberum (September 2016 - October 2021)1
• Healthcare Equity Research Analyst at Berenberg (July 2013 - September 2016)1
• Healthcare Equity Research Analyst at Liberum (August 2011 - July 2013)1

Education

• Bachelor of Arts (B.A.), Economics, 1.1 from Trinity College, Dublin (2007 - 2011)1

Stock Coverage and Performance

As an analyst at UBS, Graham Doyle currently covers 16 stocks across the healthcare sector with a 51% success rate and an average return of -6.6%.3 Some of his recent notable ratings include:

• Alcon (ALC): Buy rating with a $102.68 price target (July 2024)4
• Koninklijke Philips (PHG): Neutral rating (April 2024)2
• GE HealthCare Technologies (GEHC): Neutral rating with an $88 price target (February 2024)2